Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $729.06 million. The enterprise value is $441.49 million.
| Market Cap | 729.06M |
| Enterprise Value | 441.49M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 64.92 million shares outstanding. The number of shares has increased by 4.24% in one year.
| Current Share Class | 64.92M |
| Shares Outstanding | 64.92M |
| Shares Change (YoY) | +4.24% |
| Shares Change (QoQ) | +4.73% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 86.69% |
| Float | 48.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 14.69 |
| PB Ratio | 2.59 |
| P/TBV Ratio | 2.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.43, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.43 |
| Quick Ratio | 7.27 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.54% and return on invested capital (ROIC) is -212.89%.
| Return on Equity (ROE) | -55.54% |
| Return on Assets (ROA) | -33.91% |
| Return on Invested Capital (ROIC) | -212.89% |
| Return on Capital Employed (ROCE) | -77.47% |
| Weighted Average Cost of Capital (WACC) | 3.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.93M |
| Employee Count | 109 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.19% in the last 52 weeks. The beta is -0.06, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | +56.19% |
| 50-Day Moving Average | 16.56 |
| 200-Day Moving Average | 15.84 |
| Relative Strength Index (RSI) | 33.08 |
| Average Volume (20 Days) | 830,411 |
Short Selling Information
The latest short interest is 7.64 million, so 11.77% of the outstanding shares have been sold short.
| Short Interest | 7.64M |
| Short Previous Month | 7.63M |
| Short % of Shares Out | 11.77% |
| Short % of Float | 15.85% |
| Short Ratio (days to cover) | 6.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -218.81M |
| Pretax Income | -203.47M |
| Net Income | -210.71M |
| EBITDA | -218.52M |
| EBIT | -218.81M |
| Earnings Per Share (EPS) | -$3.43 |
Balance Sheet
The company has $289.57 million in cash and $2.00 million in debt, with a net cash position of $287.57 million or $4.43 per share.
| Cash & Cash Equivalents | 289.57M |
| Total Debt | 2.00M |
| Net Cash | 287.57M |
| Net Cash Per Share | $4.43 |
| Equity (Book Value) | 281.28M |
| Book Value Per Share | 4.33 |
| Working Capital | 258.02M |
Cash Flow
In the last 12 months, operating cash flow was -$165.46 million and capital expenditures -$11,000, giving a free cash flow of -$165.47 million.
| Operating Cash Flow | -165.46M |
| Capital Expenditures | -11,000 |
| Depreciation & Amortization | 290,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -165.47M |
| FCF Per Share | -$2.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGEM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.24% |
| Shareholder Yield | -4.24% |
| Earnings Yield | -30.56% |
| FCF Yield | -22.70% |
Analyst Forecast
The average price target for CGEM is $34.70, which is 208.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.70 |
| Price Target Difference | 208.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |